Cost Pressures Prompt Possible Fee Increases In Australia
Regulator Proposes Potentially Slower Drug Reviews Or Higher Fees
Executive Summary
The Australian regulator, the TGA, is having to deal with increased cost pressures stemming from a rise in applications for unauthorized drugs, including medicinal cannabis.
You may also be interested in...
New Filings At The EMA
New medicines under evaluation at the European Medicines Agency.
UK: Commercial Framework Sheds Light On Working With NHS And NICE
The final text brings some changes, including the introduction of an escalation process when companies and NHS England cannot agree.
Time Is Ripe For Global Action On Orphan Biosimilars
European industry association wants global convergence on development requirements, though the European Medicines Agency says that this would prove challenging.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: